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Abstract: Recent epidemiological studies and animal experiments have demonstrated that 
nonsteroidal antiinﬂ  ammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma. 
Cyclooxygenase (COX) is the principal target of NSAIDs. COX is the ﬁ  rst oxidase in the 
process of prostaglandin production from arachidonic acid. COX enzyme may be involved 
in the initiation and/or the promotion of carcinogenesis due to NSAIDs inhibition of COX. 
Lipoxygenase (LOX) is also an initial enzyme in the pathway for producing leukotrienes 
from arachidonic acid. Similar to COX, LOX enzyme may also be involved in the initiation 
and/or promotion of carcinogenesis. Peroxisome proliferator activator-receptor (PPAR)-γ is a 
ligand-activated transcriptional factor belonging to the steroid receptor superfamily. PPAR-γ 
plays a role in both adipocyte differentiation and carcinogenesis. PPAR-γ is one target for 
cell growth modulation of NSAIDs. In this review, we report the expression of COX-2, LOX 
and PPAR-γ in human renal cell carcinoma tissues as well as the effects of COX-2 and LOX 
inhibitors and PPAR-γ ligand.
Keywords: cyclooxygenase, lipoxygenase, peroxisome proliferator activator-receptor-γ, renal 
cell carcinoma
Introduction
Recently, with increased routine medical check-ups and progress in diagnostic imaging 
techniques, the discoveries of renal cell carcinoma (RCC) have increased. The cause of 
RCC is unknown. RCC generally does not respond well to radiotherapy and chemotherapy 
compared to many other types of cancers, and anticancer drugs as interferon-α and inter-
leukin-2 is used with relative success. So surgery is currently the only therapeutic option. 
Hence, new molecular targets are needed for the prevention and treatment of RCC.
Nonsteroidal antiinﬂ  ammatory drugs (NSAIDs) have anticancer effects for the 
RCC patient, thus, attracting a great deal of attention. The typical target of NSAIDs 
is cyclooxygenase (COX). In recent reports, a number of patients have had signiﬁ  -
cantly low risks of colorectal cancer while they continued using NSAIDs typiﬁ  ed by 
aspirin. Consequently, the suppression of carcinogenesis by administering NSAIDs 
has come into focus. It was also reported that the size and number of adenoma were 
markedly reduced when sulindac, a type of NSAIDs was given to patients with familial 
adenomatous polyposis, a high risk group for colorectal cancer (Sano et al 1995).
It is known that NSAIDs inhibit the activity of COX and production of prostaglandin. 
NSAIDs also stimulate peroxisome proliferator activator-receptor (PPAR)-γ and inhibit 
the production of chemical mediators such as tumor necrosis factor-α, interleukin-1β 
and interleukin-6 through the expression of PPAR-γ in leukocytes. PPAR-γ is thus a 
promising target for cell growth modulation by NSAIDs.
In this review, we discuss the possibility that the target of arachidonic acid pathway 
metabolite may be a new anticancer strategy for human RCC.OncoTargets and Therapy 2008:1 42
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Arachidonic acid pathway
The metabolism of arachidonic acid by either COX pathway 
or lipoxygenase (LOX) pathway generates eicosanoids, 
which have been implicated in the pathogenesis of a variety 
of human diseases, including cancer, and are considered 
important in tumor promotion, progression, and metastasis 
(Yoshimura et al 2003a).
COX is the ﬁ  rst enzyme in the pathway for producing 
prostaglandin (PG) and thromboxane (Tx) from arachidonic 
acid, and can occur as three isoforms, COX-1, COX-2, and 
COX-3. The enzymes of both COX-1 and COX-2 are trans-
formed from the cell membrane phospholipid to arachidonic 
acid by the phospholipase A2, and then transform arachidonic 
acid to PGH2 through PGG2. COX-1 occurs in tissues and 
cells and works to protect the cell. COX-2 express momen-
tarily and strongly in response to growth factors and some 
endotoxins. It is involved with inﬂ  ammation, cell prolifera-
tion and differentiation (Xie et al 1991). Recently, COX-2 has 
also been shown to play an important role in carcinogenesis 
(Sano et al 1995). Although the existence of COX-3 has 
recently been reported, it continues to be argued.
LOX is the ﬁ  rst enzyme in the pathway for producing 
leukotriene (LT) from arachidonic acid. Isoenzymes of 
LOX include 5-LOX, 12-LOX, and two 15-LOX isoforms 
(15-LOX-1, 15-LOX-2). These catalyze the biosynthesis of 
biologically active compounds such as LTs and hydroxyeico-
satetraenoic acids (HETEs) (Sigal 1991; Funk 1996). 5-LOX 
catalyzes the ﬁ  rst step in oxygenation of arachidonic acid to 
produce 5-hydroperoxyeicosatetraenoic acid (5-HPETE), 
and the subsequent metabolism of 5-HPETE to 5-HETE 
and LTs. LTs belong to an important group of proinﬂ  am-
matory mediators that are synthesized from arachidonic 
acid via the 5-LOX pathway. The activity of 5-LOX leads 
to the formation of unstable LTA4, which can be converted 
into either LTB4, or cysteinyl LTs (LTC4, LTD4 and LTE4) 
(Matsuyama et al 2007).
The 12-LOX, includes platelet 12-LOX, and leukocyte 
12-LOX that oxygenate arachidonic acid at position 
C-12 to produce 12-hydroperoxyeicosatetra- enoic acid and 
then 12-HETE (Yoshimura et al 2003a). Whereas 5-LOX, 
12-LOX, and 15-LOX-1, have procarcinogenic roles, 
15-LOX-2 appears to have an anticarcinogenic roles.
PPAR
PPARs are members of the nuclear receptor super-family 
of ligand-activated transcriptional factor such as steroids, 
thyroid hormone, vitamin D3 and retinoic acid (Issemann 
and Green 1990). PPAR binds to peroxisome proliferator 
response element (PPRE) as a heterodimer with the retinoic 
receptor (RXR) in the regulation of PPAR target genes. 
PPARs may be important immunomodulatory factors as well 
as fatty acid regulators. PPARs modulate these activities in 
different immune cell types such as monocyte/macrophages, 
lymphocytes, and endothelial cells.
Three PPAR subtypes (α, β, and-γ) have been identi-
ﬁ  ed. PPAR-α is highly expressed in the liver, heart, kidney, 
muscle, brown adipose tissue, and gut tissues which exhibit 
high carbolic rates towards fatty acid (Braissant et al 1996). 
PPAR-β is expressed ubiquitously, and its function is 
relatively unknown (Mukherjee et al 1997). Recent studies 
suggest that PPAR-β may be a target for NSAID-induced 
tumor suppression in colorectal tumors. PPAR-γ is expressed 
at high-level in adipose tissue and is a critical regular of 
adipocyte differentiation. In addition, PPAR-α and -γ may 
be important immunomodulatory factors. PPAR-α-knockout 
mice exhibit exacerbated inﬂ  ammatory responses, and LTB4, 
a chemotactic mediator, seems to regulate the clearance of 
itself as an agonist of PPAR-α. PPAR-γ is also expressed in 
the immune system tissues and cells (spleen, bone-marrow, 
monocytes, helper T-cell clones) and skeletal tissues (bone, 
synovioum, chondrocytes) (Braissant et al 1996).
Recent data have shown that PPAR-γ ligands lead 
to inhibition of phorbol ester-induced nitric oxide and 
macrophage-derived cytokines. PPAR-γ ligands also induce 
apoptosis in macrophage, ﬁ  broblasts, and endothelial cells 
(Kawahito et al 2000). PPAR-γ plays a role in both adipocyte 
differentiation and carcinogenesis. PPAR-γ ligands lead 
to inhibition of the expression of nitric oxide, cytokines, 
chemokines and adhesion molecules, in part by antagonizing 
the activities of transcriptional factors. Furthermore, 
PPAR-γ ligands including antidiabetic thiazolidinedione 
(such as troglitazone) and 15-deoxy-Δ12, 14 -prostaglandin J2 
(15-d-PGJ2) have potent tumor modulatory effects on several 
cancers (Tsubouchi et al 2000; Inoue et al 2001).
COX and RCC
COX-2 expression in RCC tissues was stronger than in 
the normal kidney (NK) tissues by immunohistochemical 
staining (Figure 1) (108 RCC and 20 NK tissues) or reverse 
transcriptase polymerase chain reaction (RT-PCR). We clas-
siﬁ  ed 3 categories (epithelium, blood vessel, a small quantity 
of stromal tissue) in RCC tissues, and examined them for 
intensity of COX-2 expression. COX-2 expression was more 
intensive and extensive in all categories of RCC tissues than 
NK tissues. Signiﬁ  cant differences occurred between grades 
of RCC tissues in only epithelium in COX-2 expression. OncoTargets and Therapy 2008:1 43
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COX-2 expression was stronger in high differentiation RCC 
(Yoshimura et al 2004a).
Hashimoto and colleagues (2004) reported COX-2 
expression was strong in RCC by immunohistochemical 
staining, and there was a correlation between the expres-
sion of COX-2, grade and stage. Miyata and colleagues 
(2003) reported there was only correlation between COX-2 
expression and more than 7 cm length tumor by immunohis-
tochemical straining. Mungan and colleagues (2006) reported 
COX-2 expression was signiﬁ  cantly higher in RCC and renal 
intratubular neoplasia than the normal and pyelonephritic 
cases by immunohistochemisty. Sozen and colleagues (2007) 
reported RCC patients with higher immunohistochemical 
COX-2 staining score values have signiﬁ  cantly shorter 
progression-free survival rates.
The establishment of cancer tissue requires that it 
should permeate through the mucosa and the submucosa 
after it destroys the basement membrane. Consequently, the 
destructive action of tumor cells on the basement membrane 
is an integral part in the development of a tumor in its ﬁ  rst 
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Figure 1 COX-2 immunostaining in RCC and normal kidney (NK) tissues. COX-2 was strongly expressed in all slides from cancer specimens, clear cell RCC -G1, -G2 and 
G3 (B, C and D) and other types of RCC tissues (E; papillary RCC G3, F; collecting duct carcinoma chromophobe RCC G2, G; chromophobe RCC G2). No expression of 
COX-2 was detected in NK tissue (A). Immunostaining with PBS was negative (H).OncoTargets and Therapy 2008:1 44
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stage, and the activation of matrix meta protease is essential 
for the destruction of the basement membrane. Miyata and 
colleagues (2003) reported the correlation between the devel-
opment of the RCC and the activation of matrix meta protease-
2 based on its involved with the expression of COX-2 in the 
tumor. Smyth and colleagues (2003) reported RCC depresses 
the immunocompetence, and vascularization, while producing 
PGE2 in the development of tumor growth.
Cyclooxygenase-2 (COX-2) and vascular endothelial 
growth factor (VEGF) are frequently up-regulated 
in malignant tumors and play a role in proliferation, 
apoptosis, angiogenesis and tumor invasion. Hemmerlein 
and colleagues (2004) reported COX-2 and VEGF are 
expressed in RCC and associated cell populations such as 
endothelia and monocytes/macrophages by RT-PCR and 
immunohistochemistry.
A recently accepted explanation is that only celecoxib, 
among the COX-2 inhibitors induces apoptosis of cancer 
cells. Rini and colleagues (2006) reported maximal COX-2 
tumor immunostaining might identify RCC patents more 
likely to achieve clinical beneﬁ  t with COX-2 inhibition by 
celecoxib in combination with interferon-α.
In our experiment, we could not demonstrate signiﬁ  cant 
apoptosis induction by administering eight kinds of COX-2 
inhibitors into the human RCC cell line (Caki-1) (Table 1). 
Additionally, we could not demonstrate the signiﬁ  cance 
of both selective COX-2 inhibitor (etodolac, meloxicam, 
nimesulide and NS398) and relatively poor selective 
COX-2 inhibitor (ibuprofen, indomethacin, piroxicam and 
s-naparoxen) (Yoshimura et al 2004b).
In conclusion, COX-2 expression is strong in RCC, but 
the anticancer effect of COX-2 inhibitor is very weak in RCC 
patients in a single administration at a clinical dose. COX-2 
inhibitor is suitable for chemopreventive therapy.
LOX and RCC
We have shown that 5- and 12-LOX expressions in 
RCC tissues were stronger than those in NK tissues by 
immunohistochemical staining (50 RCC and 10 NK 
tissues) and RT-PCR (Figure 2). We classiﬁ  ed 3 categories 
(epithelium, blood vessel, a small quantity of stromal tissue) 
in RCC tissues and NK tissues, and examined the intensity of 
5- and 12-LOX expressions. 5- and 12-LOX expressions were 
more intensive and extensive in all categories of RCC tissues 
as compared with NK tissues (Table 2). There were signiﬁ  -
cant differences only epithelium in RCC tissues, and 5- and 
12-LOX expressions were stronger in high differentiation 
RCC (Matsuyama et al 2005).
Table 1 Effects of COX and LOX inhibitors, and PPAR-γ ligand in viabity of human RCC cell line (Caki-1)
5 μM 10 μM 20 μM 40 μM 80 μM
COX-2 inhibitor
Selective COX-2 inhibitor
Etodolac not shown 116.6% 114.4% 95.7% 96.3%
Meloxicam not shown 115.2% 106.0% 99.5% 68.2%
Nimesulide not shown 96.0% 104.2% 103.1% 93.5%
NS398 not shown 110.5% 86.1% 79.8% 73.2%
Poor selective COX-2 
inhibitor
Ibuprofen not shown 108.4% 108.7% 104.9% 110.2%
Indometacin not shown 114.1% 112.9% 114.0% 102.9%
Piroxicam not shown 87.4% 96.7% 85.8% 83.3%
S-naproxen not shown 95.2% 102.8% 103.1% 93.5%
LOX inhibitor
5-LOX inhibitor (Caffeic acid) not shown 92.4% 68.3% 21.7% 16.6%
12-LOX inhibitor (Baicalein) not shown 103.5% 98.7% 75.2% 40.6%
Non selective LOX inhibitor 
(NDGA)
not shown 72.5% 28.7% 8.6% 9.8%
PPAR-γ ligand
Troglitazone 22.1% 16.6% 13.4% 10.7% not shown
15-d-PGJ2 69.8% 54.2% 20.3% 16.8% not shown
Notes: The dose-response analysis of viability in human RCC cell line (Caki-1) treated with COX-2 and LOX inhibitors, and PPAR-γ ligand (5–80 μM, 48 hr) was measured 
by the MTT assay and expressed as % of control culture conditions.OncoTargets and Therapy 2008:1 45
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At 10–80 μM, some, but not all LOX inhibitors reduced the 
viability of RCC cell line (Caki-1) by MTT assay (Table 1). 
5-LOX inhibitor appeared more potent than the 12-LOX 
inhibitor (Matsuyama et al 2004). RCC cells treated with some 
LOX inhibitor (50 μM) also showed chromatin condensation, 
cellular shrinkage, apoptotic bodies and cytoplasmic conden-
sation by hoechest staining (Figure 3). RCC cells treated with 
5-LOX inhibitor (100 μM) entered early apoptosis, but not late 
apoptosis, necrosis or DNA fragmentation by ﬂ  ow cytometry. 
However, PPAR-γ ligands did not cause normal proximal 
tubular endothelial cells (PRTEC) to undergo apoptosis.
Faronato and colleagues (2007) reported increased 
5-LOX protein and mRNA correlated with large tumor 
size ( 4 cm) and age of patients. In contrast, there was 
no association between 5-LOX and gender, grade or vein 
invasion by quantitative PCR. VEGF expression was strongly 
inducible by 5-LOX metabolites in RCC cell lines. They 
suggest that 5-LOX up-regulation is an important step in 
RCC progression (Faronato et al 2007).
In conclusion, 5-LOX expression is strong in RCC. 
The anticancer effect of 5-LOX inhibitor is signiﬁ  cantly 
stronger than those of COX-2 inhibitor. The anticancer 
effect of 5-LOX inhibitor is weak in RCC patients in a single 
administration at a clinical dose. 5-LOX inhibitor is suitable 
for chemopreventative therapy, like COX-2 inhibitor.
PPAR-γ and RCC
By immunohistochemical staining (126 RCC and 20 NK 
tissues) and RT-PCR, PPAR-γ expression was increased in 
RCC tissues as compared with NK tissues (Inoue et al 2001). 
All categories (epithelium, blood vessel, a small quantity 
of stromal tissue) of RCC tissues were more extensive than 
NK tissues in PPAR-α, -β, and -γ expression. There were 
no signiﬁ  cant differences between grades and stages of 
RCC tissues in all categories in PPAR-α, and -β expres-
sion. However, PPAR-γ expression was higher in G1 cancer 
than in G3 cancer, and there were no signiﬁ  cant differences 
among stages.
The PPAR-γ ligands troglitazone and 15-d-PGJ2 induced 
the reduction of RCC cell line (Caki-1) viability in the range 
of 10–40 μM by using MTT assay (Table 1). RCC cells treated 
with PPAR-γ ligands (25 μM troglitazone and 15-d-PGJ2) 
entered early apoptosis, but not late apoptosis, necrosis or 
DNA fragmentation by ﬂ  ow cytometry. However, PPAR-γ 
ligands did not cause normal proximal tubular endothelial cells 
(PRTEC) to undergo apoptosis (Figures 4, 5). PPAR-γ ligands 
also induced apoptosis in RCC cells at 20 μM by hoechest 
staining (Yoshimura et al 2003b).
Yang and colleagues (2005) reported PPAR-γ was 
expressed at much higher levels in RCC than in NK. 
PPAR-γ ligands (troglitazone) inhibited RCC cell growth in 
a dose-dependent manner. Generally, Bcl-2 is a key factor 
suppressing the apoptosis accompanying of caspase. Consis-
tent with our ﬁ  ndings, they also reported 50 μM troglitazone 
induced massive apoptosis in RCC cells with decreased Bcl-2 
expression (Yang et al 2005). Yuan and colleagues (2005) 
reported that PPAR-γ were expressed in RCC cell lines by 
RT-PCR and immunocytochemical staining. PPAR-γ ligands 
inhibited the cell growth in all cells in a dose-dependent 
manner through apoptosis. Secretion of both VEGF and basic 
ﬁ  broblast growth factor was inhibited by PPAR-γ ligands in a 
dose-dependent and time-dependent manner (Yuan et al 2005). 
They also reported that PPAR-γ mRNA expression in RCC 
cells did not affect cell growth inhibition by PPAR-γ ligands 
(Yuan et al 2006).
In conclusion, PPAR-γ is strongly expressed in RCC, 
and the anticancer effect of PPAR-γ ligand is signiﬁ  cantly 
greater than that of 5-LOX inhibitor. The anticancer effect 
of PPAR-γ ligand is relatively weak. Targeting PPAR-γ in 
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Figure 2 RT-PCR analysis of 5- and 12-LOX in RCC tissues and normal kidney (NK) 
tissues. Using speciﬁ  c primers for 5-LOX, 12-LOX and G3PDH, the ampliﬁ  cation 
predicted fragments of 337 bp for 5-LOX, 345 bp for 12-LOX and 598 bp for G3PDH 
in length.  A; 5-LOX, B; 12-LOX, C; G3PDH. Lane 1; markers, Lane 2; NK tissues, Lane 3; 
RCC tissues. RCC tissues expressed signiﬁ  cant 5- and 12-LOX mRNA bands while 
NK tissues expressed no 5- and 12-LOX mRNA bands.OncoTargets and Therapy 2008:1 46
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Table 2 Statistical analysis of 5-LOX and 12-LOX immunostaining
Epithelium Blood vessel Stromal tissue
5-LOX
 RCC 2.8 ± 0.8* 2.6 ± 0.6* 2.7 ± 0.7*
   G1 3.2 ± 0.7* 2.8 ± 0.6* 2.9 ± 0.7*
   G2 2.6 ± 0.6* 2.4 ± 0.5* 2.6 ± 0.7*
   G3 1.9 ± 0.5* 2.3 ± 0.4* 2.3 ± 0.4*
  Normal kidney (NK) 0.6 ± 0.4 0.5 ± 0.4 0.6 ± 0.5
12-LOX
 RCC 2.4 ± 0.7* 2.2 ± 0.5* 2.1 ± 0.6*
   G1 2.8 ± 0.5* 2.3 ± 0.6* 2.2 ± 0.7*
   G2 2.2 ± 0.6* 2.1 ± 0.6* 2.0 ± 0.5*
   G3 1.7 ± 0.5* 2.1 ± 0.3* 1.9 ± 0.3*
  Normal kidney (NK) 0.5 ± 0.4 0.6 ± 0.4 0.6 ± 0.4
Notes: Graded 0–4 on the coded sections by two observers in a blinded manner. 0, no staining; 4, maximum intensity. Statistical analysis was performed using the ANOVA 
(p-value). 5- and 12-LOX immunostaining was signiﬁ  cantly more extensive and intense in tumor cells than in tissue of normal kidney. (*P  0.001).
A B
C D
Figure 3 Effects of LOX inhibitor in induction of apoptosis on RCC cells. Human RCC cell line (Caki-1) treated with 5-LOX inhibitor caffeic acid (B), and nonspeciﬁ  c 
LOX inhibitor NDGA (D) showed chromatin condensation, cellular shrinkage, small membrane-bound bodies (apoptotic bodies), and cytoplasmic condensation. Cells with 
12-LOX inhibitor baicalein only slightly showed the same apoptotic changes (C). In contrast, untreated cells (A) maintained normal chromatin patterns and cell size.OncoTargets and Therapy 2008:1 47
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Figure 4 Effects of PPAR-γ ligand on apoptosis by ﬂ  ow cytometry in RCC cells. Human RCC cell line (Caki-1) with treatment of PPAR-γ ligand (25 μM troglitazone and 
15-d-PGJ2) could induce early apoptosis not late apoptosis or necrosis. PPAR-γ ligand (25 μM) did not cause normal proximal tubular endothelial cells (PRTEC) to undergo 
apoptosis. The top left quadrants represent early apoptosis (Annexin V-FITC-positive cells and PI-negative cells). The top right quadrants represent late apoptosis or necrosis 
(Annexin V-FITC-positive cells and PI-positive cells). Diagrams of FITC-Annexin V/PI ﬂ  ow cytometry are presented.
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Figure 5 PPAR-γ ligand induced DNA fragmentation in RCC cells. PPAR-γ ligand (25 μM troglitazone and 15-d-PGJ2) could induce DNA fragmentation in human RCC cell 
line (Caki-1). PPAR-γ ligand (25 μM) did not cause normal proximal tubular endothelial cells (PRTEC) to undergo apoptosis. Typical ﬂ  ow cytometry analysis histograms are 
presented.OncoTargets and Therapy 2008:1 48
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RCC is likely to be useful more as chemopreventive rather 
than a chemotherapeutic.
Conclusions
There is no argument that COX-2, LOX (especially, 
5-LOX) PPAR-γ are involved in the initiation and promo-
tion of RCC tissues. It may be possible to use COX-2 and 
5-LOX inhibitors, and PPAR-γ ligand as anticancer drugs 
for chemopreventive therapy in a single administration of 
a clinical dose. However, it may be difﬁ  cult to use COX-2 
and 5-LOX inhibitors, even with PPAR-γ ligand in single 
administration of a clinical dose as a potential chemothera-
peutic therapy. The clinical application of PPAR-γ ligand and 
5-LOX inhibitor require further research and consideration, 
as the target of PPAR-γ ligand and 5-LOX inhibitor remains 
a novel strategy in treating human RCC.
We conclude the administration of COX-2 and 5-LOX 
inhibitor, and PPAR-γ ligand are useful along with conventional 
treatment of human RCC. The combination therapy of COX-2 
and 5-LOX inhibitor, and PPAR-γ ligand may be a beneﬁ  cial 
new treatment of human RCC.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
Braissant O, Foufelle F, Scotto C, et al. 1996. Differential expression 
of peroxisome proliferator-activated receptors (PPARs). Tissue 
distribution of PPAR-alpha, -beta, and –gamma in the adult rat. 
Endocrinology, 137:354–66.
Faronato M, Muzzonigro G, Milanese G, et al. 2007. Increased expression 
of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histol 
Histopathol, 22:1109–18.
Funk CD. 1996. The molecular biology of mammalian lipoxygenases and 
the quest for eicosanoid functions using lipoxygenase-deﬁ  cient mice. 
Biochim Biophys Acta, 11:65–84.
Hashimoto Y, Kondo Y, Kimura G, et al. 2004. Cyclooxygenase-2 expression 
and relationship to tumour progression in human renal cell carcinoma. 
Histopathology, 44:353–9.
Hemmerlein B, Galuschka L, Putzer N, et al. 2004. Comparative 
analysis of COX-2, vascular endothelial growth factor and 
microvessel density in human renal cell carcinomas. Histopathology, 
45:603–11.
Inoue K, Kawahito Y, Tsubouchi Y, et al. 2001. Expression of peroxisome 
proliferator-activated receptor gamma in renal cell carcinoma and 
growth inhibition by its agonists. Biochem Biophys Res Commun, 
287:727–32.
Issemann I, Green S. 1990. Activation of a member of the steroid 
hormone receptor superfamily by peroxisome proliferator. Nature, 
347:645–50.
Kawahito Y, Kondo M, Tsubouchi Y, et al. 2000. 15-deoxy-delta(12,14)-PGJ(2) 
induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis 
in rats. J Clin Invest, 106:189–97.
Matsuyama M, Hayama T, Funao K, et al. 2007. Overexpression of 
cysteinylLT1 receptor in prostate cancer and CysLT1R antagonist 
inhibits prostate cancer cell growth through apoptosis. Oncol Rep, 
18:99–104.
Matsuyama M, Yoshimuira R, Tsuchida K, et al. 2004. Lipoxygenase 
inhibitors prevent urological cancer cell growth. Int J Mol Med, 
13:665–8.
Matsuyama M, Yoshimura R, Mitsuhashi M, et al. 2005. 5-lipoxygenase 
inhibitors attenuate growth of human renal cell carcinoma and induce 
apoptosis through arachidonic acid pathway. Oncol Rep, 14:73–9.
Miyata Y, Koga S, Kanda S, et al. 2003. Expression of cyclooxygenase-2 in 
renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, 
angiogenesis, expression of matrix metalloproteinase-2, and survival. 
Clin Cancer Res, 9:1741–9.
Mukherjee R, Jow L, Croston GE, et al. 1997. Identiﬁ  cation, characterization, 
and tissue distribution of human peroxisome proliferator-activated 
receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and 
activation with retinoid X receptor agonists and antagonists. J Biol 
Chem, 272:8071–6.
Mungan MU, Gurel D, Canda AE, et al. 2006. Expression of COX-2 in 
normal and pyelonephritic kidney, renal intraepithelial neoplasia, and 
renal cell carcinoma. Eur Urol, 50:23–5.
Rini BI, Weinberg V, Dunlap S, et al. 2006. Maximal COX-2 
immunostaining and clinical response to celecoxib and interferon 
alpha therapy in metastatic renal cell carcinoma. Cancer, 
106:566–75.
Sano H, Kawahito Y, Wilder RL, et al. 1995. Expression of cyclooxygenase-1 
and –2 in human colorectal cancer. Cancer Res, 55:3785–9.
Sigal E. 1991. The molecular biology of mammalian arachidonic acid 
metabolism. Am J Physiol, 260:13–28.
Smyth GP, Stapleton PP, Barden CB, et al. 2003. Renal cell carcinoma 
induces prostaglandin E2 and T-helper type 2 cytokine production in 
peripheral blood mononuclear cells. Ann Surg Oncol, 10:455–62.
Sozen S, Gurocak S, Erdem O, et al. 2007. Cyclooxygenase-2 expression: 
Does it have a probable role in tumorigenesis mechanisms of renal cell 
carcinoma? Int Urol Nephrol, 26.
Tsubouchi Y, Sano H, Kawahito Y, et al. 2000. Inhibition of human lung 
cancer cell growth by the peroxisome proliferator-activated receptor-γ 
agonists through induction of apoptosis. Biochem Biophys Res Commun, 
270:400–5.
Xie W, Chipman JG, Robertson DL, et al. 1991. Expression of a 
mitogen-responsive gene encoding prostaglandin synthase is regulated 
by mRNA splicing. Proc Natl Acad Sci U S A, 88:2692–6.
Yang FG, Zhang ZW, Zin DQ, et al. 2005. Peroxisome proliferator-activated 
receptor gamma ligands induce cell cycle arrest and apoptosis in human 
renal carcinoma cell lines. Acta Pharmacol Sin, 26:753–61.
Yoshimura R, Matsuyama M, Hase T, et al. 2003b. The effect of peroxisome 
proliferator-activated receptor-gamma ligand on urological cancer cells. 
Int J Mol Med, 12:861–5.
Yoshimura R, Matsuyama M, Kawahito Y, et al. 2004a. Study of 
cyclooxygenase-2 in renal cell carcinoma. Int J Mol Med, 13:229–33.
Yoshimura R, Matsuyama M, Kawahito Y, et al.2004b. The effect of 
cyclooxygenase-2 inhibitors on urological cancer cells. Int J Mol Med, 
13:789–93.
Yoshimura R, Matsuyama M, Tsuchida K, et al.2003a. Expression of 
lipoxygenase in human bladder carcinoma and growth inhibition by 
its inhibitors. J Urol, 170:1994–9.
Yuan J, Takahashi A, Masumori N, et al. 2005. Ligands for peroxisome 
proliferator-activated receptor gamma have potent antitumor effect 
against human renal cell carcinoma. Urology, 65:594–9.
Yuan J, Takahashi A, Masumori N, et al. 2006. Peroxisome proliferator-
activated receptor gamma is frequently underexpressed in renal cell 
carcinoma. Int J Urol, 13:265–70.